Comparative effectiveness of biguanides versus SGLT2 inhibitors on cardiovascular and cerebrovascular events, diabetic nephropathy, retinopathy, neuropathy, and treatment expenditures in patients with type 2 diabetes
Using a large-scale regional database from Japan, we found that among adults with type 2 diabetes without prior major cardiac or renal disease, first-line treatment with an SGLT2 inhibitor did not reduce risks of cardio-cerebrovascular events, mortality, or complications compared with metformin, and cost about 50% more.
Authors
- Hiromichi Yui
- Takayoshi Nagahama
- Hiromitsu Ohno
- Taku Matsunaga
- Chikara Ueki
- Emi Ohata (ORCID: https://orcid.org/0000-0002-8862-877X)
- Toru Tonoike
- Daito Funaki (ORCID: https://orcid.org/0009-0009-2566-9839)
- Hideaki Kaneda
- Akinori Miyakoshi (ORCID: https://orcid.org/0000-0001-7547-2828)
- Akira Sugawara (ORCID: https://orcid.org/0000-0003-4511-8101)
- Hiraku Kumamaru (ORCID: https://orcid.org/0000-0002-9759-6191)
- Eiji Nakatani (ORCID: https://orcid.org/0000-0002-4876-446X)
- Yoshihiro Tanaka (ORCID: https://orcid.org/0000-0002-7468-8886)
- Ataru Igarashi (ORCID: https://orcid.org/0000-0001-6307-6916)
- Tatsunori Satoh (ORCID: https://orcid.org/0000-0002-1756-3147)
Institutions
- Nagoya City University (JP)
- Advanced Engineering Services (Japan) (JP)
- Shizuoka General Hospital (JP)
- The University of Tokyo (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1371/journal.pone.0336038
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29